|
|
|
Agenus and BMS Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
“AGEN1777’s differentiated mechanism of action provides the potential for potent anti-tumor activity; catalyzing our clinical TIGIT strategy aimed at serving more patients with unmet needs in cancer,” said Debbie Law, D.Phil., Senior Vice President, Head of Tumor Microenvironment Thematic Research Center, Bristol Myers Squibb. “We look forward to working with Agenus to develop this important therapy as we continue to combat I-O resistance.”
Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708
“This agreement validates the capabilities of our drug discovery engine and represents a significant milestone for our CD73 program,” said Susan Molineaux, PhD, president and chief executive officer of Calithera. “Antengene brings significant enthusiasm and proven global capabilities to the development and future commercialization of CB-708, a potential best-in-class oral small molecule CD73 inhibitor. This licensing agreement enables the continued advancement of this promising program, while allowing Calithera to focus our resources on our more advanced clinical programs evaluating telaglenastat in non-small cell lung cancer and CB-280 in cystic fibrosis.”
|
|
|
Ginkgo Bioworks and Biogen collaborate over $120 million deal to develop AAV vectors to the cutting edge
Ginkgo Bioworks (Ginkgo; Boston) is a biotechnology company with expertise in genetic and cell engineering to deliver products across industries (from agriculture to pharmaceuticals). Ginkgo recently went public through a merger with a special purpose acquisition company (SPAC) called Soaring Eagle Acquisition Corp., earning a $15 billion evaluation. In the context of the Covid-19 pandemic, Ginkgo offered its robotic cell and genetic programing platform to Moderna to finetune the latter’s mRNA vaccine performance.
On 21st May 2021, Ginkgo and Biogen Inc. (Biogen, Cambridge MA) announced a partnership of $120 million to increase the manufacturability of adeno-associated virus (AAV)-based vectors. For doing this, Biogen will pay $5 million in upfront cash and $115 million as milestone payments to Ginkgo. Ginkgo in turn will use its technological platforms to reprogram the genome of mammalian cell lines and revamp the AAV DNA sequence to increase functional compatibility and drive AAV production to the maximum.
This deal will enable Biogen with its new gene therapy investments in Alzheimer’s and Parkinson’s disease by increasing effective gene delivery to neurons. For Ginkgo, this is an opportunity to prove their capability in gene therapy, an erstwhile unchartered territory, with the potential for massive business opportunities and establishing a strong biotech presence in the future.
|
|
Click here for more on mergers, acquisition and business news
|
|
|
Disclaimer
The editors take care to share authentic information. In case of any discrepancies please write to medness.newsletter@gmail.com
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Medness. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for Medness. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
|
|
|
|
|
|
|